v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash Flows From Operating Activities:              
Net income (loss) $ (1,919,071) $ (6,698,242) $ 8,048,936 $ 21,721,858 $ (9,299,498) $ 24,388,307  
Adjustments to reconcile net income (loss) to net cash flows used in operating activities:              
Depreciation and amortization 635,661   123,059   1,646,207 239,630  
Stock-based compensation         1,028,084 1,148,327  
Change in fair value of warrant derivative liabilities (1,164,849)   (11,585,204)   (6,726,638) (33,274,039)  
Gain on extinguishment of warrant derivative liabilities         (3,624,794)  
Provision for inventory obsolescence         143,664 339,668  
Provision for doubtful accounts receivable         (161,239) (527)  
Gain on extinguishment of debt     (10,000)  
Change in fair value of short-term investments         28,210  
Change in fair value of contingent consideration promissory note 138,877     (347,169)  
Increase (decrease) in:              
Accounts receivable – trade         143,937 337,364  
Accounts receivable – other         (3,426,732) 111,768  
Inventories         (1,448,044) (1,767,724)  
Prepaid expenses         531,508 (3,445,546)  
Operating lease right of use assets         306,783 (27,875)  
Other assets         (4,125,776) (752,324)  
Accounts payable         5,133,934 (475,256)  
Accrued expenses         (106,800) 209,833  
Income taxes payable         9,969 (5,331)  
Operating lease obligations         (306,782) 14,757  
Contract liabilities         2,831,394 709,977  
Net cash used in operating activities         (17,797,992) (12,230,781)  
Cash Flows from Investing Activities:              
Purchases of property, plant and equipment         (1,947,127) (5,575,021)  
Additions to intangible assets         (158,218) (239,139)  
Cash paid for TicketSmarter acquisition, net of cash acquired         (8,361,808)  
Restricted cash related to TicketSmarter acquisition           (500,000)  
Cash paid for acquisition of Medical Billing Company         (1,153,627) (1,012,552)  
Cash paid for asset acquisition of Medical Billing Company         (230,000) (2,270,000)  
Net cash used in investing activities         (3,488,972) (17,958,520)  
Cash Flows from Financing Activities:              
Repurchase and cancellation of common stock         (4,026,523)  
Distribution to noncontrolling interest in consolidated subsidiary         (15,692)  
Net proceeds from sale of common stock in registered direct offerings         13,346,600  
Proceeds from issuance of common stock upon exercise of pre-funded warrants         53,224,000  
Principal payment on contingent consideration promissory notes         (383,222)  
Net cash (used in) provided by financing activities         (4,425,437) 66,570,600  
Net increase (decrease) in cash and cash equivalents         (25,712,401) 36,381,299  
Cash, cash equivalents, beginning of period   $ 32,007,792   $ 4,361,758 32,007,792 4,361,758 $ 4,361,758
Cash, cash equivalents, end of period $ 6,295,391   $ 40,743,057   6,295,391 40,743,057 $ 32,007,792
Supplemental disclosures of cash flow information:              
Cash payments for interest         44,783  
Cash payments for income taxes         9,969 7,581  
Supplemental disclosures of non-cash investing and financing activities:              
Issuance of contingent consideration promissory note for business acquired         855,000 5,244,400  
Issuance of common stock through warrant exchange agreement         4,495,500  
Assets acquired in business acquisitions         190,631 7,366,399  
Liabilities assumed in the business acquisition         387,005 5,494,417  
Goodwill acquired in business acquisitions         2,100,000  
Common stock issued as consideration for business acquisition         990,360  
Restricted common stock grant         715 856  
Restricted common stock forfeitures         65 8  
Amounts allocated to initial measurement of warrant derivative liabilities in connection with the warrants and pre-funded warrants         $ 51,216,058